CULVER CITY, Calif., April 15, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for ...

ImmunityBio, Inc.’s IBRX share price has dipped by 6.65%, which has investors questioning if this is right time to buy.

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s worst-performing stocks. Wall Street’s main indices suffered a bloodbath on ...

We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s ...

We recently published a list of Biotech Stocks Dominate Monday’s Top 10 Gainers. In this article, we are going to take a look ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other stocks that outperformed broader market last week. Wall Street’s main indices traded ...

The latest analyst rating for ImmunityBio (NASDAQ:IBRX) was provided by D. Boral Capital, and ImmunityBio maintained their buy rating. The last downgrade for ImmunityBio Inc happened on May 12 ...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA ® (nogapendekin alfa inbakicept-pmln ...